|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
oncology
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2004
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XX32
|
|
gptkbp:can_be_combined_with
|
radiation therapy
chemotherapy
|
|
gptkbp:casnumber
|
216974-75-3
|
|
gptkbp:chemical_formula
|
C6630 H10240 N1710 O2100 S44
|
|
gptkbp:clinical_trial
|
gptkb:RTOG_0825
Phase III
ECOG 4599
AVF2107g
AVF2192g
AVF3708g
|
|
gptkbp:clinical_use
|
combination therapy
monotherapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Avastin
|
|
gptkbp:indication
|
gptkb:disease
gptkb:Oncology
gptkb:cervical_cancer
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_a_guide_for
|
ASCO Guidelines
NCCN Guidelines
ESMO Guidelines
|
|
gptkbp:manufacturer
|
gptkb:Genentech
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkb:Bevacizumab
|
|
gptkbp:mechanism_of_action
|
inhibits angiogenesis
|
|
gptkbp:research_areas
|
anti-angiogenic therapy
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:side_effect
|
gptkb:anemia
dizziness
fatigue
headache
nausea
hypertension
diarrhea
rash
bleeding
gastrointestinal perforation
proteinuria
hypoalbuminemia
thromboembolism
infusion reactions
wound healing complications
stomatitis
|
|
gptkbp:targets
|
gptkb:vascular_endothelial_growth_factor_(VEGF)
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:bfsLayer
|
4
|